MK-4830

N/A

Report date: 2024/06/27 20:00:09
First In Class

Base Information

Drug NameMK-4830
Drug Alias NameMK-4830
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAgenus Inc
China Registration ClassN/A

Develop Information

Active CompaniesAgenus IncWerthenstein Biopharma GmbhMerck Sharp & Dohme Corp +[5] 
Inactive CompaniesMsd Ireland (Carlow)
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Inactive IndicationsEsophageal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A